Dispensing Study to Assess Visual Performance of Prototype Contact Lenses

Brien Holden Vision Institute (BHVI)

Status: Completed

Conditions: Refractive Error; Presbyopia

Treatments: Device: Etafilcon A, Lotrafilcon B , Senofilcon A

Study type: Interventional

Funder types: Industry

Identifiers

NCT02214797

CRTC2013-02

ACTRN12614000011684 (Registry Identifier)

Details and patient eligibility

About

The aim of this study is to assess visual performance of prototype soft contact lens designs compared to commercially available contact lenses over one-week of lens wear.

Full description

Prospective, participant-masked, multiple arm, crossover dispensing clinical trial where participants will wear prototype (test) and commercial (control) lenses bilaterally. Participants will be stratified based on their refractive error into either presbyopic or non-presbyopic group. Each of the stratified group will have a maximum of 4 parallel arms. Up to 4 test lens designs will be assessed against the control/s in each parallel arm in a randomized cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit.

Enrollment: 67 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent
• Be at least 18 years old, male or female
• Willing to comply with the wearing and clinical trial visit schedule as directed by the Investigator
• Have ocular health findings considered to be "normal" and which would not prevent the participant from safely wearing contact lenses
• Correctable to at least 6/12 (20/40) or better in each eye with contact lenses
• Be willing to not wear contact lenses for a minimum of 2 days before each stage of the clinical trial (after informed consent)

Exclusion criteria

• Any pre-existing ocular irritation, injury or condition (including infection or disease) of the cornea, conjunctiva or eyelids that would preclude contact lens fitting and safe wearing of contact lenses
• Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjögrens syndrome and systemic lupus erythematosus. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants
• Use of or a need for concurrent category S3 and above ocular medication at enrolment and/or during the clinical trial
• Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant's ocular health / physiology or contact lens performance either in an adverse or beneficial manner at enrolment and/or during the clinical trial NB: Systemic antihistamines are allowed on an "as needed basis", provided they are not used prophylactically during the trial and at least 24 hours before the clinical trial product is used
• Eye surgery within 12 weeks immediately prior to enrolment for this trial.
• Previous corneal refractive surgery
• Contraindications to contact lens wear
• Known allergy or intolerance to ingredients in any of the clinical trial products

The Investigator may, at his/her discretion, exclude anyone who they believe may not be able to fulfil the clinical trial requirements or it is believed to be in the participant's best interests

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Single Blind

---

67 participants in 4 patient groups

Presbyopic group - Low Add

Other group

Description:

40 years and over Add of less than +1.50D Control lens : Lotrafilcon B and Senofilcon A Test lens: Etafilcon A Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion. Each lenses will be worn for a week with a minimum 2 day washout period between the lens types. Each lens will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit.

Treatment:

Device: Etafilcon A, Lotrafilcon B , Senofilcon A

Presbyopic group - Med Add

Other group

Description:

40 years and over Add of +1.50D to +1.75D Control lens : Lotrafilcon B and Senofilcon A Test lens: Etafilcon A Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit.

Treatment:

Device: Etafilcon A, Lotrafilcon B , Senofilcon A

Presbyopic group - High Add

Other group

Description:

40 years and over Add of +2.00D to +2.50D Control lens : Lotrafilcon B and Senofilcon A Test lens: Etafilcon A Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit.

Treatment:

Device: Etafilcon A, Lotrafilcon B , Senofilcon A

Non-presbyopic group

Other group

Description:

18 to 39 years old No Add Control lens : Lotrafilcon B and Etafilcon A Test lens: Etafilcon A Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit.

Treatment:

Device: Etafilcon A, Lotrafilcon B , Senofilcon A